COVID-19 Vaccines International Pregnancy Exposure Registry
Completed
Conditions studied: Covid19
In brief
The objective of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is to evaluate obstetric, neonatal, and infant outcomes among women vaccinated during pregnancy with a COVID-19 vaccine. Specifically, the C-VIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestational diabetes, gestational hypertension, intrauterine growth restriction, postpartum hemorrhage, fetal distress, uterine rupture, placenta previa, chorioamnionitis, Caesarean delivery, COVID-19), neonatal outcomes (major congenital malformations, low birth weight, neonatal death, neonatal encephalopathy, neonatal infections, neonatal acute kidney injury, preterm birth, respiratory distress in the newborn, small for gestational age, stillbirth, COVID-19), and infant outcomes (developmental milestones \[motor, cognitive, language, social-emotional, and mental health skills\], height, weight, failure to thrive, medical conditions during the first 12 months of life, COVID-19) among pregnant women exposed to single (homologous) or mixed (heterologous) COVID-19 vaccine brand series from 30 days prior to the first day of the last menstrual period to end of pregnancy and their offspring relative to a matched reference group who received no COVID-19 vaccines during pregnancy.
Key facts
- Study ID
- NCT04705116
- Run by
- Pregistry
- People needed
- 1184
- Starts
- 2021-06-01
- Expected to finish
- 2026-04-26
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Vaccinated population:
- Pregnant at time of enrollment
- Age ≥18 years at time of enrollment
- Signed the informed consent form and submitted the baseline module "COVID-19 Vaccination During This Pregnancy"
- Received at least one dose of a COVID-19 vaccine during pregnancy or within the 30 days prior to the first day of the LMP
- Resident of a country where a Central Institutional Review Board (IRB) or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study
- Efforts will be made to obtain documentary evidence of COVID-19 vaccination.
- Comparison population:
- Pregnant at time of enrollment
- Age ≥18 years at time of enrollment
- Signed the informed consent form and submitted the minimum required data in the initial baseline questionnaire
- Have not received a COVID-19 vaccine during pregnancy or within the 30 days prior to the first day of the LMP
- Resident of a country where a Central IRB or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study
You may not qualify if…
- Not pregnant at time of enrollment
- Age <18 years at time of enrollment
Where it is running
- Pregistry — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.